Gå til hovedindhold


CHRETO is developing a cost effective and flexible, disruptive single-use platform technology for affinity purification to be used in the biopharmaceutical industry.

Our vision is that the CHRETO technology™ will radically improve the process efficiency of downstream processing of large biomolecules. We believe that CHRETO’s Protein Purification Technology will bring a true revolution to bio-manufacturing, which has been sought by the industry for decades.

Our goals are to have the first product on market in 2018 and to position CHRETO as the preferred purification technology for monoclonal antibodies (mAb) and intravenous immunoglobulin (IVIG) going forward.